治疗慢性移植物抗宿主病新药ROCK2抑制剂Belumosudil

A New Drug for the Treatment of Chronic Graft-versus-host Disease:ROCK2 Inhibitor Belumosudil

Belumosudil是一种Rho相关卷曲螺旋蛋白激酶2的选择性口服抑制剂,该药于2021年7月16日获美国食品和药品监督管理局批准上市,用于治疗已接受过至少2种系统疗法治疗失败的慢性移植物抗宿主病儿童(年龄≥12岁)与成人患者。本文对belumosudil的作用机制、药动学、临床评价、安全性评价等进行评述。

Belumosudil is a selective oral inhibitor of Rho-associated coiled-coil containing protein kinase 2.It was approved by the U.S.Food and Drug Administration on July 16,2021 for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.The mechanism,pharmacokinetics,drug interaction,clinical evaluation,and safety of belumosudil were reviewed.